deltatrials
Active Not Recruiting INTERVENTIONAL NCT07543575

JIA Toolbox Feasibility Study

JIA (Juvenile Idiopathic Arthritis) Toolbox Feasibility Study

Sponsor: Sheffield Children's NHS Foundation Trust

Updated 1 time since 2026 Last updated: Apr 15, 2026 Started: May 21, 2024 Primary completion: Feb 28, 2026 Completion: May 31, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Juvenile Idiopahtic Arthritis and is currently ongoing. Sheffield Children's NHS Foundation Trust leads this study, which shows 1 recorded version since 2024 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Study Description(click to expand)

Juvenile idiopathic arthritis (JIA) is the most frequently occurring rheumatic disease of childhood, causing ongoing joint inflammation, pain and stiffness making everyday activities difficult. Studies have emphasised the significant negative impacts JIA has across physical, social, psychological and educational development. Key stakeholder groups (CYP with JIA, their parents, healthcare professionals and teachers) were active participants throughout our previous work, through co-design workshops, surveys and a proof-of-concept study. Key highlighted clinical need was assistance with self-management. This is broken down into the following specific unmet needs: Pain-management. Improved pain management would enable CYP to do more of the things they love, by providing a solution that they can use independently as and when is needed, positively impacting their wellbeing. Physiotherapy adherence as currently CYP often do not do clinician-recommended exercises. Improved compliance with recommended physiotherapy interventions may reduce pain in the long-term and improve mobility. Communication between the pupil and teacher. Improving this communication would provide CYP with a way to discreetly access necessary support without facing stigma, improving their concentration by removing anxiety around accessing help. JIA Toolbox is a co-designed innovation, consisting of three assistive device prototypes that aim to collectively improve condition self-management. Each prototype helps with the...

Juvenile idiopathic arthritis (JIA) is the most frequently occurring rheumatic disease of childhood, causing ongoing joint inflammation, pain and stiffness making everyday activities difficult. Studies have emphasised the significant negative impacts JIA has across physical, social, psychological and educational development.

Key stakeholder groups (CYP with JIA, their parents, healthcare professionals and teachers) were active participants throughout our previous work, through co-design workshops, surveys and a proof-of-concept study. Key highlighted clinical need was assistance with self-management. This is broken down into the following specific unmet needs:

Pain-management. Improved pain management would enable CYP to do more of the things they love, by providing a solution that they can use independently as and when is needed, positively impacting their wellbeing.

Physiotherapy adherence as currently CYP often do not do clinician-recommended exercises. Improved compliance with recommended physiotherapy interventions may reduce pain in the long-term and improve mobility.

Communication between the pupil and teacher. Improving this communication would provide CYP with a way to discreetly access necessary support without facing stigma, improving their concentration by removing anxiety around accessing help.

JIA Toolbox is a co-designed innovation, consisting of three assistive device prototypes that aim to collectively improve condition self-management. Each prototype helps with the afore-mentioned specific unmet needs

Status Flow

Apr 23, 2026 – present · 2 months · daily APIActive Not Recruiting

Change History

1 version recorded
Active Not Recruiting [daily]

Eligibility Summary

Juvenile Idiopathic Arthritis (JIA) is a long-term rheumatic disease affecting approximately 15,000 children and young people (CYP) in the UK. JIA causes ongoing/long-term joint inflammation, pain, and stiffness, making everyday activities difficult. JIA has been shown to impact physical, social, emotional, and educational development. CYP with JIA find current product aids difficult to use, stigmatising and patronising. This project follows on from a previous successful proof-of-concept study in 2021, involving initial testing on 10 CYP over 9 weeks. These results established that the prototypes addressed an unmet need and worked well. We now propose a feasibility study involving 25 children using the prototypes over 3 months to assess their suitability and further develop an evidence base. The prototypes - 'JIA Toolbox'- consist of three prototypes that collectively aim to improve CYP's independence and functional ability. This project consists of 6 Work Packages (WP): WP1: Post application and pre-award start WP2: Design and development WP3: Production of final prototypes WP4: Recruitment of participants WP5: Feasibility intervention period WP6: Data analysis and dissemination The feasibility study aims to test the effectiveness and viability of 'JIA Toolbox' in improving CYP with JIA's independence, functional ability, and therefore overall condition management. The study will involve recruiting 25 CYP with JIA aged 7-16 and their parent/guardian from Sheffield Children's Hospital. Baseline data on CYP's lived experience of JIA will be collected over 2 weeks, through self-reporting. They will then use the prototypes for 3 months. Lived experience data on condition management will continue to be self-reported and the prototypes will collect usage data independently. Post-intervention data will then be collected for a further 2 weeks. Interviews will then be conducted to further capture study experience.

Contact Information

Sponsor contact:
  • Sheffield Children's NHS Foundation Trust
  • Sheffield Hallam University
Data source: ClinicalTrials.gov

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations